AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.
AstraZeneca Inks Research Pact With China’s CSPC Pharmaceuticals Focused On AI-Driven Research, Valued Up To $5.33 Billion
